Breaking News Instant updates and real-time market news.

TWTR

Twitter

$17.56

-2.29 (-11.54%)

, CRM

Salesforce

$75.10

4.19 (5.91%)

16:23
10/10/16
10/10
16:23
10/10/16
16:23

On The Fly: Top stock stories for Monday

Stocks on Wall Street opened in positive territory and remained there throughout the entire session. The market internals were decidedly positive, with advancing names ahead of decliners by just about 3:1. Oil was strong all day as Russia said it would back a production freeze. The report pushed Brent crude to a 52-week high and put WTI in the area of its best levels of the year, near $51 per barrel. ECONOMIC EVENTS: In the U.S., no major economic reports were released and bond markets were closed for Columbus Day. In oil news, Russia said it was ready to join a proposed deal to cap oil production, sending the global benchmark, Brent crude futures, to above $53 per barrel to hit their highest level since late 2015. WTI crude futures, the U.S. benchmark, also rose about 3% to a four-month high above $51 per barrel. In Asia, Chinese mainland markets reopened after a week-long holiday, with the Shanghai Composite index adding 1.5%. However, Japan, Hong Kong, and Taiwan were all shut for trading for their own holidays. In Europe, Germany's trade numbers for August came in strong, with exports growing 5.4% and imports rising 3%, both of which were better than expected. COMPANY NEWS: Shares of Twitter (TWTR) fell 11.5% after Bloomberg reported this weekend, citing people familiar with the matter, that the social media platform company's sales process is "almost dead" as its major suitors have lost interest amid investor pressure. Big-name potential buyers that were once interested, including Alphabet's (GOOG, GOOGL) Google, Disney (DIS) and Salesforce (CRM), are unlikely to make a bid, according to Bloomberg's sources. Late in the day, Reuters issued its own update on the Twitter sales process, with its sources agreeing that Google and Disney have backed away from making offers, but contending that Salesforce is still deliberating whether it is worth making a "lowball offer" in the coming days... Mylan (MYL) shares rallied about 8% after the drugmaker agreed to a $465M settlement over charges that it overcharged the government for its EpiPen products. In conjunction with the settlement, Mylan cut its guidance for the year, citing the previously announced changes in access programs for the allergy rescue treatment and the upcoming launch of the generic to EpiPen Auto-Injector. MAJOR MOVERS: Among the notable gainers was Merck (MRK), which gained about 2% after announcing results from two studies of Keytruda in the first-line treatment of patients with metastatic non-small cell lung cancer at the European Society of Medical Oncology meeting. Also higher on the heels of the ESMO cancer congress was TESARO (TSRO), which advanced nearly 19% after a Phase 3 trial demonstrated that its niraparib treatment significantly prolonged progression free survival compared to control in ovarian cancer patients who were germline BRCA mutation carriers and in patients who were not germline BRCA mutation carriers. Among the noteworthy losers was Bristol-Myers (BMY), which fell 10% as several Wall Street analysts argued that Merck's good news was bad news for Bristol and its competing Opdivo drug. Also lower were shares of Dover (DOV), which dropped over 7.5% after the maker of energy, fluids, and refrigeration equipment cut its yearly earnings view, citing the weak global economy and weaker capital spending. INDEXES: The Dow rose 88.55, or 0.49%, to 18,329.04, the Nasdaq gained 36.27, or 0.69%, to 5,328.67, and the S&P 500 advanced 9.92, or 0.46%, to 2,163.66.

TWTR

Twitter

$17.56

-2.29 (-11.54%)

CRM

Salesforce

$75.10

4.19 (5.91%)

MYL

Mylan

$38.87

2.93 (8.15%)

MRK

Merck

$63.90

1.13 (1.80%)

BMY

Bristol-Myers

$49.81

-5.62 (-10.14%)

TSRO

TESARO

$117.91

18.65 (18.79%)

DIS

Disney

GOOG

Alphabet

$785.94

10.86 (1.40%)

GOOGL

Alphabet Class A

$814.17

13.46 (1.68%)

DOV

Dover

$66.69

-5.55 (-7.68%)

  • 11

    Oct

  • 23

    Oct

  • 25

    Oct

  • 27

    Oct

  • 27

    Oct

  • 31

    Oct

  • 06

    Nov

  • 09

    Nov

  • 10

    Nov

  • 10

    Nov

  • 17

    Nov

  • 30

    Nov

  • 11

    Jan

  • 15

    Jan

  • 28

    Mar

TWTR Twitter
$17.56

-2.29 (-11.54%)

10/10/16
JPMS
10/10/16
NO CHANGE
Target $95
JPMS
Overweight
JPMorgan sees 'opportune entry point' for Salesforce
JPMorgan analyst Mark Murphy believes shares of Salesforce (CRM) are at an "'opportune entry point" following the recent selloff. The pullback has been driven by a "slightly soft" Q2 and concerns about a potentially expensive acquisition of Twitter (TWTR), Murphy tells investors in a research note. After speaking to industry contacts at Dreamforce, the analyst sees a path for the "overhangs to fade" with a "better pace of business in Q3/Q4" as well as the eventual fading of the Twitter discussion. Murphy reiterates an Overweight rating on Salesforce with a $95 price target in a research note titled "The Most Valuable Cloud Asset Is Undeservedly Undervalued."
10/07/16
ADAM
10/07/16
NO CHANGE
Target $95
ADAM
Buy
Salesforce worthy of investor consideration at current levels, says Canaccord
Canaccord analyst Richard Davis came away from the Salesforce (CRM) Dreamforce week more enthused about the company's outlook. The analyst noted the company is growing its revenues 3.5 times faster than it legacy peers. Davis noted the company's CEO said they are very disciplined on price when it comes to acquisitions and believes that they would not be interested in Twitter (TWTR) at its rumored asking price of $28 per share. Davis reiterated his Buy rating and $95 price target on Salesforce shares.
10/07/16
PIPR
10/07/16
NO CHANGE
Target $100
PIPR
Overweight
Piper sees 'clouds parting' on Salesforce valuation
Salesforce CEO Marc Benioff mostly calmed nerves over a potential Twitter (TWTR) acquisition by saying at the company's analyst day, "While we look at everything, we pass on almost everything," Piper Jaffray analyst Alex Zukin tells investors in a research note. The comment does not completely take a deal for Twitter off the table, but the probability of a transformational acquisition is now "dramatically lower," Zukin contends. As such, the analyst feels the "clouds are parting" on Salesforce's valuation "with sunshine ahead." Zukin believes the company has a "clear line of sight" to $10B in revenue in FY17. He keeps an Overweight rating on the shares with a $100 price target. Salesforce closed yesterday up $2.84, or 4%, to $71.26.
10/06/16
BMOC
10/06/16
NO CHANGE
BMOC
Twitter acquisition would hurt Salesforce, says BMO Capital
BMO Capital analyst Keith Bachman says that an acquisition of Twitter (TWTR) by Salesforce (CRM) would " offer little strategic fit, would slow revenue growth and would be dilutive to (free cash flow) margins." Bachman thinks that the deal would cause Salesforce's stock to drop significantly,. and he says that the company's stock would be worth $65 if it pulls the trigger on Twitter. The analyst says that Salesforce's current valuation is attractive if it does not buy Twitter. He keeps an $86 price target and Outperform rating on Salesforce.
CRM Salesforce
$75.10

4.19 (5.91%)

MYL Mylan
$38.87

2.93 (8.15%)

10/10/16
RAJA
10/10/16
UPGRADE
Target $57
RAJA
Strong Buy
Mylan upgraded to Strong Buy on EpiPen settlement at Raymond James
As previously reported, Raymond James upgraded Mylan two notches to Strong Buy from Market Perform and established a $57 price target. Analyst Elliot WIlbur said the Department of Justice settlement over EpiPen rebates eliminates a significant overhang on shares enabling the focus to be back on fundamentals. With depressed absolute and relative valuation levels, Wilber sees favorable risk/reward scenarios even in a more tempered earnings growth environment.
10/10/16
10/10/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Mylan (MYL) upgraded to Strong Buy from Market Perform at Raymond James with Elliot WIlbur saying the Department of Justice settlement over EpiPen rebates eliminates a significant overhang on shares enabling the focus to be back on fundamentals. 2. Under Armour (UA) upgraded to Outperform from Market Perform at Wells Fargo with analyst Tom Nikic saying "noise" from the Sports Authority's bankruptcy is fading while distribution expansion could lead to sales re-acceleration over the next 12-18 months. 3. Deere (DE) and AGCO (AGCO) were upgraded to Outperform from Market Perform at Wells Fargo. 4. Dow Chemical (DOW) upgraded to Buy from Neutral at UBS with analyst John Roberts saying the merger with DuPont (DD) could gain regulatory approval and that the stock is "now too cheap to ignore." 5. Exelixis (EXEL) upgraded to Overweight from Neutral at Piper Jaffray with analyst Edward Tenthoff saying the data are "good enough" to file a supplemental new drug application and could drive off-label front-line RCC use. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/10/16
WELS
10/10/16
NO CHANGE
WELS
Mylan settlement does not end EpiPen issue, says Wells Fargo
In a research note titled "Forget After Hrs. Quarterbacking - It is Not Back to Normal," Wells Fargo analyst David Maris says Mylan questions still remain after the company's lowered 2016 outlook and $465M Department of Justice settlement. One of Mylan's earnings levers, EpiPen pricing, is now off the table going forward, Maris tells investors in a research note. The analyst disagrees with investors that think the settlement puts the EpiPen pricing issue largely behind the company. The deal with the DOJ addresses only the Centers for Medicare and Medicaid Services portion of the issue, it does nothing to answer the original issue of EpiPen pricing and consumers, Maris contends. He points out that Mylan also disclosed in Friday's regulatory filing, but not in its press release, an SEC investigation by the Division of Enforcement. Maris says he's "not too excited" and doesn't gauge how good the news is by the after-hours share rally of 10%. He believes Mylan is "not back to normal" and keeps a Market Perform rating on the stock with a $43-$45 price target range. The shares are up 12% in pre-market trading to $40.35. Raymond James this morning upgraded Mylan to Strong Buy.
10/10/16
JPMS
10/10/16
NO CHANGE
Target $52
JPMS
Overweight
Mylan settlement, updated guidance a positive, says JPMorgan
JPMorgan analyst Chris Schott views Mylan's $465M settlement with the Department of Justice relating to the potential misclassification of Epipen in the Medicaid Drug Rebate Program as well as its updated 2016 guidance as a positive. The news "removes litigation overhang at a reasonable cost and highlights the diversification of the base business and inexpensive valuation," Schott tells investors in a research note. He keeps an Overweight rating on Mylan with a $52 price target.
MRK Merck
$63.90

1.13 (1.80%)

10/10/16
JMPS
10/10/16
NO CHANGE
JMPS
Incyte treatment looking 'promising,' says JMP Securities
After reviewing recent data, JMP Securities analyst Liisa Bayko says that the combination of Incyte's (INCY) Epacadostat plus Merck's (MRK) Keytruda is "emerging as a promising treatment, potentially even best in class." The analyst says that the progression free survival rate of the combination in melanoma patients "is emerging to be quite competitive," while the efficacy rate in other solid tumors "seemed encouraging." The analyst raised her price target on Incyte to $110 from $100 and keeps an Outperform rating on the stock.
10/10/16
LEER
10/10/16
NO CHANGE
LEER
Market Perform
Merck 'steals the show' at ESMO with Keytruda data, says Leerink
Leerink analyst Seamus Fernandez said Merck (MRK) stole the show at ESMO with its Keytruda data and he continues to think the company will dominate first line lung cancer treatment for years to come in patients with 50%+ PDL1 expression. Additionally, he expects Merck to gain additional traction in the overall market, noting that confirmation that Keytruda is benefiting patients when combined with Alimta/carboplatin with Alimta maintenance raises the possibility Merck could compete broadly in the overall non-squamous patient population. However, Fernandez keeps a Market Perform rating on Merck, as he thinks its current valuation largely reflects improved growth prospects through 2020.
10/10/16
LEER
10/10/16
NO CHANGE
LEER
Outperform
Leerink sees Bristol-Myers sliding after Merck's 'spectacular' Keytruda data
Leerink analyst Seamus Fernandez said Bristol-Myers' (BMY) Checkmate-026 data presented at the European Society of Medical Oncology meeting was disappointing, noting there was no signal of benefit on progression-free survival or overall survival and only "modest differentiation" on response rate in the 88 patients with PDL1 biomarker positivity greater than or equal to 50%. Meanwhile, Merck (MRK) presented "spectacular" data for Keytruda monotherapy at the meeting, said Fernandez, who expects Bristol shares to be down "significantly" today in light of the meeting presentations. The analyst, who still thinks Bristol has a significant opportunity to compete with Merck's Keytruda in the PDL1 high portion of the market, keeps an Outperform rating on Bristol shares, which are down nearly 6% in pre-market trading.
10/10/16
BMOC
10/10/16
NO CHANGE
BMOC
Merck should strengthen leadership in first line NSCLC, says BMO Capital
BMO Capital analyst Alex Arfaei says that upcoming data should strengthen Merck's (MRK) lead in 1L NSCLC. The analyst adds that the data could support off-label use of Merck's Keytruda in additional 1L NSCLC patients, and he says that the data "should be negative" for Bristol-Myers' (BMY) Opdivo drug. Arfaei keeps an Outperform rating on Merck and a Market Perform rating on Bristol-Myers.
BMY Bristol-Myers
$49.81

-5.62 (-10.14%)

09/20/16
SBSH
09/20/16
NO CHANGE
Target $70
SBSH
Buy
Bristol-Myers price target lowered to $70 from $75 at Citi
In a research note titled "Brace Yourself. Attractive Valuation but No Near-Term Respite.," Citi analyst Andrew Baum lowered his price target for shares of Bristol-Myers Squibb to $70 from $75. The analyst lowered his earnings forecasts by up to 8% to reflect the "limited supportive data" in the non-small cell lung cancer indication. Baum keeps a Buy rating on the shares as he views the valuation as attractive. He points out, however, the near-term news-flow is likely to be negative.
09/27/16
PIPR
09/27/16
NO CHANGE
Target $62
PIPR
Neutral
Bristol-Myers price target lowered to $62 from $65 at Piper Jaffray
Piper Jaffray analyst Richard Purkiss lowered his price target for Bristol-Myers Squibb (BMY) to $62 saying he sees the company ceding Opdivo's early-mover advantage in lung cancer to competitors. The analyst expects to see details from Roche's (RHHBY) positive OAK trial of Tecentriq vs. docetaxel in non-small cell lung cancer at the upcoming ESMO meeting. Purkiss also expects to see details from Merck's (MRK) positive KEYNOTE-024 trial of Keytruda. The analyst lowered his post-2016 Opdivo forecasts and reiterates a Neutral rating on Bristol shares.
09/28/16
ROTH
09/28/16
NO CHANGE
Target $23
ROTH
Buy
Nektar price target raised to $23 from $19 at Roth Capital
Roth Capital analyst Michael Higgins raised his price target for Nektar (NKTR) to $23 from $19 after the company and Bristol-Myers (BMY) announced a clinical collaboration to evaluate the combination of the latter's anti-PD-1 antibody, Opdivo, with NKTR-214. The analyst reiterates a Buy rating on Nektar's shares.
TSRO TESARO
$117.91

18.65 (18.79%)

10/10/16
RAJA
10/10/16
NO CHANGE
Target $120
RAJA
Strong Buy
TESARO price target raised to $120 at Raymond James
Raymond James analyst Christopher Raymond raised TESARO's price target to $120 from $105 fter the company reported "clinically meaningful benefits in all the sub-populations" of the NOVA trial for niraparib. Raymond thinks niraparib will have a broad ovarian cancer label and corresponding market opportunity and reiterates his Strong Buy rating.
10/10/16
FBCO
10/10/16
NO CHANGE
Target $122
FBCO
Outperform
TESARO price target raised to $122 on Niraparib data at Credit Suisse
Credit Suisse analyst Alethia Young raised TESARO's price target to $122 from $90 after the company reported "clinically meaningful benefits in all the sub-populations" of the NOVA trial for niraparib. The analyst thinks niraparib has broad effects across the 2nd line ovarian population and would expect the label is broad. Young has an Outperform ratting n TESARO shares.
10/10/16
RAJA
10/10/16
NO CHANGE
Target $120
RAJA
Outperform
TESARO price target raised to $120 from $105 at Raymond James
Raymond James analyst Christopher Raymond raised TESARO's price target to $120 from $105 after the company reported "clinically meaningful benefits in all the sub-populations" of the NOVA trial for niraparib. Raymond thinks niraparib will have a broad ovarian cancer label and corresponding market opportunity and reiterates his Strong Buy rating
10/10/16
RBCM
10/10/16
NO CHANGE
RBCM
TESARO price target raised to $128 from $122 at RBC Capital
RBC Capital analyst Adnan Butt raised his price target on TESARO after ovarian cancer patients taking the company's Niraparib drug responded better than expected. Butt said that the drug benefited the patients regardless of BRCA or HRD biomarker status. He keeps an Outperform rating on the stock.
DIS Disney

09/27/16
SBSH
09/27/16
NO CHANGE
Target $16
SBSH
Neutral
Citi sees 40% downside in Twitter with no takeover bid
Citi analyst Mark May believes Twitter's (TWTR) risk/reward skews to the downside following the recent rally in the shares. A buyout of the company carries "strategic rationale for certain companies," but Twitter's "struggles and steep valuation" make a deal at a meaningful premium less likely, May tells investors in a research note. A takeover at $26 per share looks aggressive, May contends. He believes the stock could retest the lows of late May, representing 40% downside from current levels, should an acquisition offer not materialize. The analyst keeps a Neutral rating on Twitter with a $16 price target. The shares closed yesterday up 75c to $23.37 following reports that Disney (DIS) may be joining the list of potential acquires that already includes Alphabet (GOOG) and Salesforce (CRM).
09/28/16
SBSH
09/28/16
NO CHANGE
SBSH
Buy
Citi hopes Disney does not acquire Twitter
Citi analyst Jason Bazinet lays out four reasons for why he doesn't like Disney (DIS) pursuing an acquisition of Twitter (TWTR). Going back 15 years, the analyst can't think of a single web-based property that was successfully acquired by a traditional media firm. Two, he calls Twitter trends "troubling." Three, Bazinet estimates a cash offer would lower Disney's stock by $5 per share while an equity offer would drop its stock by $9. Four, the analyst feels it is unclear how Disney's content will help Twitter. Bazinet thinks both Yahoo (YHOO) and Twitter lost "significant money" when they streamed NFL content over the web. The analyst hopes Twitter is acquired by somebody other than Disney. He keeps a Buy rating on Disney shares. Both Loop Capital and Mizuho this morning downgraded Twitter to sell ratings.
10/06/16
SBSH
10/06/16
NO CHANGE
Target $89
SBSH
Buy
Citi says Salesforce buying Twitter 'nearly impossible' above $28/share
Citi analyst Walter Pritchard believes a Salesforce (CRM) acquisition of Twitter (TWTR) is possible financially but that such a deal would put "significant constraints" on the company for the next three-plus years. The analyst sees "very little reason" for Salesforce to own Twitter and feels the acquisition "would pose a difficult decision" for CEO Marc Benioff and the board. Salesforce closed yesterday down 6%, or $4.21, to $68.42. Recode reported last night that the company is likely the only bidder left for Twitter after Disney (DIS) and Alphabet (GOOG) opted not to pursue a deal while Apple (AAPL) is unlikely. Twitter in pre-market trading is down 14% to $21.50. In order for Salesforce to avoid a shareholder vote, it would have to borrow $7.5B to fund the transaction if Twitter were valued at $20B, or $27.50-$28 per share, Pritchard tells investors in a research note. This is a level that likely constrains the company with little additional borrowing capacity for other deals, the analyst contends. He thinks the deal is "nearly impossible to do" for Salesforce should the bidding for Twitter go above $20B or $28 per share. Pritchard has a Buy rating on Salesforce with an $89 price target.
10/10/16
DBAB
10/10/16
INITIATION
Target $90
DBAB
Sell
Deutsche sees Netflix takeover as unlikely, starts shares at Sell
Deutsche Bank analyst Bryan Kraft initiated shares of Netflix (NFLX) with a Sell rating and $90 price target. The stock closed Friday down 25c to $104.82. The risk/reward is unattractive as consensus expectations reflect an "optimistic case," Kraft tells investors in a research note. Market expectations appear too high through 2020, the analyst contends. He also expresses skepticism that Netflix will be acquired. The business is "too fully formed" and valued to be acquired by Disney (DIS) and Apple (AAPL), Kraft writes. He also sees Amazon.com (AMZN) as a competitive risk to Netflix.
GOOG Alphabet
$785.94

10.86 (1.40%)

09/28/16
09/28/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Alphabet (GOOG, GOOGL) downgraded to Underperform from Neutral at Wedbush with analyst James Dix citing concerns that the "Four Horsemen of the Search Apocalypse" -- self-identified consumers, consumer control of IP-delivered ads, payments innovation, and attention markets -- might arrive. 2. AT&T (T) downgraded to Neutral from Buy at UBS with analyst John Hodulik citing expectations for lower earnings growth. 3. Macy's (M) downgraded to Neutral from Outperform at Credit Suisse with analyst Michael Exstein saying the retailer, after outlining in August its operations and merchandising strategies, is now in an execution phase. 4. Twitter (TWTR) downgraded to Underperform from Neutral at Mizuho and to Sell from Hold at Loop Capital. 5. Galectin Therapeutics (GALT) downgraded to Sell from Buy at Roth Capital with analyst Sa'ar Yaniv citing the company's announcement that NASH-FX, GR-MD-02's Phase 2a study in NASH fibrosis, failed both primary and secondary endpoints. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/28/16
MZHO
09/28/16
DOWNGRADE
Target $15
MZHO
Underperform
Mizuho cuts Twitter to Underperform with $15 price target
Mizuho analyst Neil Doshi downgraded Twitter to Underperform from Neutral based on valuation. The shares are up 45% since the company reported Q2 results, primarily driven by potential buyout comments in media reports, Doshi tells investors in a research note. The stock at current levels is overvalued as Twitter's business fundamentals "have deteriorated significantly" over the past 12 months, the analyst contends. Doshi believes many of the M&A scenarios are unlikely to play out. He puts potential acquirers Salesforce (CRM) and Alphabet (GOOG, GOOGL) in the "maybe" camp, but he still has some reservations about these deals happening. The analyst believes investors of both companies would view a buyout of Twitter as negative. Doshi keeps a $15 price target for Twitter shares. The stock closed yesterday up 35c to $23.72. Loop Capital this morning also downgraded Twitter to Sell.
10/10/16
WELS
10/10/16
NO CHANGE
WELS
Alphabet, Facebook can meet Street estimates, says Wells Fargo
Wells Fargo says that investors are concerned about the ability of Facebook (FB) and Google (GOOG,GOOGL) to meet Street estimates because forecasts continue to indicate that TV's ad share will be relatively stable over the next two years. But Wells says that Facebook and Google will continue to gain share from "non-TV media" and could see increased revenue from "non-advertising marketing services" such as sponsorships and public relations. Wells keeps Outperform ratings on both stocks.
GOOGL Alphabet Class A
$814.17

13.46 (1.68%)

09/30/16
RBCM
09/30/16
NO CHANGE
RBCM
Street underestimating Google growth outlook, says RBC Capital
RBC Capital analyst Mark Mahaney expects Google to end 2016 with "up to 20% growth," versus the Street's outlook of mid teen percentage level growth. Mahaney says that Google's growth should be boosted by "ongoing Search innovations, rising Mobile CPCs, and the growing impact of YouTube, Play & Cloud." He thinks that YouTube's revenue is growing at a 30%-40% clip. Mahaney raised his price target on the stock to $1,025 from $1,000 and keeps an Outperform rating on the shares.
DOV Dover
$66.69

-5.55 (-7.68%)

07/13/16
BOFA
07/13/16
NO CHANGE
Target $85
BOFA
Buy
Dover price target raised to $85 from $75 at BofA/Merrill
BofA/Merrill analyst Andrew Obin raised Buy rated Dover's price target to $85 from $75 based on a higher multiple driven by higher energy estimates and strategic nationality on the Energy business.
10/07/16
SUSQ
10/07/16
INITIATION
Target $77
SUSQ
Neutral
Dover initiated with a Neutral at Susquehanna
Susquehanna analyst Robert Barry initiated Dover with a Neutral and a $77 price target.
07/26/16
BOFA
07/26/16
NO CHANGE
BOFA
Dover added ot hte US 1 List at BofA/Merrill
BofA/Merrill added Dover to the US 1 List saying Energy downside appears limited and overall earnings appear to be stabilizing.
06/10/16
06/10/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on the today's top five analyst upgrades with this list compiled by The Fly: 1. Dover (DOV) upgraded to Outperform from Market Perform at Bernstein with an $87 price target. The firm thinks that the oil-related headwinds the company had been experiencing have peaked. It says that the company's non-oil business now accounts for 93% of its earnings, up from about 60% previously, and Bernstein expects those units to generate low to mid single digit percentage organic growth. Additionally, the firm is extremely upbeat on the company's acquisition of Wayne, saying that the deal increases the value of Dover's stock by $7 per share. 2. Joy Global (JOY) upgraded to Outperform from Market Perform at FBR Capital by analyst Lucas Pipes, who also raised its price target for shares to $25 from $14. The analyst has increased confidence Joy's growth opportunities following its strategic wins in India and the Canadian oil sands and notes the company's organic order rate is tracking well against his estimates. 3. Ducommun (DCO) upgraded to Buy from Hold at Canaccord, which raised its price target to $23 from $19 on Ducommun shares. The firm cited better visibility, execution and de-leveraging of its balance sheet. The recent divestitures are expected to significantly contribute to improved margins, the firm said. 4. Pentair (PNR) upgraded to Buy from Neutral at Seaport Global by analyst Ryan Cassil, who raised his price target to $70 from $59. The analyst believes the worst margin performance is behind the company in its V&C segment and has increased confidence in management's forecast for decrementals to be reduced by half in Q2 as volumes increase seasonally and high-cost inventory is turned. 5. U.S. Concrete (USCR) upgraded to Buy from Neutral at Sidoti by analyst Michael Conti, who raised his price target to $90 from $72. The analyst views the capital raise from debt refinancing as a catalyst for acquisitions. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

MEI

Methode Electronics

$39.00

0.45 (1.17%)

06:53
12/08/16
12/08
06:53
12/08/16
06:53
Earnings
Methode Electronics reports Q2 EPS 66c, consensus 55c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

VRNT

Verint

$38.30

0.1 (0.26%)

06:52
12/08/16
12/08
06:52
12/08/16
06:52
Recommendations
Verint analyst commentary  »

Verint removed from Focus…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

AMC

AMC Entertainment

$32.65

-1.15 (-3.40%)

, CKEC

Carmike Cinemas

$33.45

-0.4 (-1.18%)

06:49
12/08/16
12/08
06:49
12/08/16
06:49
Hot Stocks
AMC Entertainment and Carmike Cinemas announce election deadline »

AMC Theatres (AMC) and…

AMC

AMC Entertainment

$32.65

-1.15 (-3.40%)

CKEC

Carmike Cinemas

$33.45

-0.4 (-1.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SCBFF

Standard Chartered

$8.68

0.28 (3.33%)

06:47
12/08/16
12/08
06:47
12/08/16
06:47
Periodicals
StanChart sanctions investigation nearing completion, Bloomberg reports »

U.S. investigators have…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HP

Helmerich & Payne

$80.86

0.94 (1.18%)

06:46
12/08/16
12/08
06:46
12/08/16
06:46
Downgrade
Helmerich & Payne rating change  »

Helmerich & Payne…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LULU

lululemon

$59.84

2.6 (4.54%)

06:45
12/08/16
12/08
06:45
12/08/16
06:45
Upgrade
lululemon rating change  »

lululemon upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jan

PRGO

Perrigo

$83.94

-0.53 (-0.63%)

06:44
12/08/16
12/08
06:44
12/08/16
06:44
Hot Stocks
Perrigo announces portfolio review developments, intends to restructure BCH unit »

Perrigo announced its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CEB

CEB

$59.50

0.35 (0.59%)

06:43
12/08/16
12/08
06:43
12/08/16
06:43
Downgrade
CEB rating change  »

CEB downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UHS

Universal Health

$111.36

-15.01 (-11.88%)

06:42
12/08/16
12/08
06:42
12/08/16
06:42
Hot Stocks
Universal Health issues statement on recent BuzzFeed article »

Universal Health issued a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

GOOGL

Alphabet Class A

$791.47

15.29 (1.97%)

, GOOG

Alphabet

$771.19

12.08 (1.59%)

06:42
12/08/16
12/08
06:42
12/08/16
06:42
Recommendations
Alphabet Class A, Alphabet, Facebook, Amazon.com analyst commentary  »

Citi replaces Amazon with…

GOOGL

Alphabet Class A

$791.47

15.29 (1.97%)

GOOG

Alphabet

$771.19

12.08 (1.59%)

FB

Facebook

$117.95

0.64 (0.55%)

AMZN

Amazon.com

$770.42

5.7 (0.75%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Jan

SMG

Scotts Miracle-Gro

$92.84

2.01 (2.21%)

06:41
12/08/16
12/08
06:41
12/08/16
06:41
Upgrade
Scotts Miracle-Gro rating change  »

Scotts Miracle-Gro…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARAY

Accuray

06:40
12/08/16
12/08
06:40
12/08/16
06:40
Hot Stocks
Accuray reports first patients treated with new Radixact system »

Accuray announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

TAX

Liberty Tax

$13.35

0.5 (3.89%)

06:38
12/08/16
12/08
06:38
12/08/16
06:38
Earnings
Liberty Tax reports Q2 EPS (72c), consensus (71c) »

Reports Q2 revenue $7.2M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

ZEN

Zendesk

$21.15

-0.02 (-0.09%)

06:38
12/08/16
12/08
06:38
12/08/16
06:38
Conference/Events
Zendesk management to meet with William Blair »

Group luncheon with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

AMZN

Amazon.com

$770.42

5.7 (0.75%)

06:38
12/08/16
12/08
06:38
12/08/16
06:38
Periodicals
Amazon seeks to help publishers profit more from ads, WSJ says »

Amazon is advancing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INFN

Infinera

$8.48

0.01 (0.12%)

06:37
12/08/16
12/08
06:37
12/08/16
06:37
Conference/Events
Infinera management to meet with William Blair »

Group luncheon with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

LLL

L-3 Communications

$161.56

3.1 (1.96%)

06:36
12/08/16
12/08
06:36
12/08/16
06:36
Downgrade
L-3 Communications rating change  »

L-3 Communications…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLL

Ball Corp.

$75.58

1.38 (1.86%)

06:34
12/08/16
12/08
06:34
12/08/16
06:34
Recommendations
Ball Corp. analyst commentary  »

Ball Corp. recent…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

YGE

Yingli Green Energy

$3.23

0.12 (3.86%)

06:34
12/08/16
12/08
06:34
12/08/16
06:34
Hot Stocks
Yingli Green Energy sees Q4 PV module shipments 600MW-670MW »

Based on current market…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

MPLX

MPLX

$31.69

-0.01 (-0.03%)

06:34
12/08/16
12/08
06:34
12/08/16
06:34
Upgrade
MPLX rating change  »

MPLX upgraded to Buy from…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

YGE

Yingli Green Energy

$3.23

0.12 (3.86%)

06:34
12/08/16
12/08
06:34
12/08/16
06:34
Earnings
Yingli Green Energy reports Q3 EPS (28c), may not compare to consensus ($1.39) »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

SAIC

SAIC

$82.12

0.28 (0.34%)

06:32
12/08/16
12/08
06:32
12/08/16
06:32
Hot Stocks
SAIC CEO says 'business development activities continue to gain momentum' »

"SAIC's third…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

SAIC

SAIC

$82.12

0.28 (0.34%)

06:31
12/08/16
12/08
06:31
12/08/16
06:31
Hot Stocks
SAIC reports Q3 net bookings approximately $1.9B »

Net bookings for the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

JNPR

Juniper

$27.75

0.82 (3.04%)

06:31
12/08/16
12/08
06:31
12/08/16
06:31
Upgrade
Juniper rating change  »

Juniper upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

SLG

SL Green Realty

$111.01

1.24 (1.13%)

06:31
12/08/16
12/08
06:31
12/08/16
06:31
Downgrade
SL Green Realty rating change  »

SL Green Realty…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.